Skip to NavigationSkip to content

News

0
PhRMA has launched a lawsuit agaisnt the state of California over a new law which requires drugmakers to notify the state and health insurers of...
0
Throughout 2017, it has emerged that the FDA has issued a record low number of warning letters to pharmaceutical firms over misrepresentation of...
0
Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary endpoint of...
0
Only last month, the story broke that Teva was looking to cut away a number of employees, the rumours have now intensified with reports...

Features

Andrew Lane, Executive Vice President of Established Pharmaceuticals at Abbott, discusses the key steps to be taken when reaching out to the...